ADVENTRX to Present at 7th Annual Fortis Biotech Conference
April 11 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, April 11 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
today announced that Evan M. Levine, chief executive officer, will
present a corporate overview at the 7th Annual Fortis Biotech
Conference on April 25 at 1.45 p.m. British Summer Time (8:45 a.m.
Eastern Daylight Time). The conference is being held at the Four
Seasons Hotel, Park Lane, London. A link to the live webcast of the
presentation can be accessed via the "Investors" section of the
Company's corporate web site at http://www.adventrx.com/ under
"Events." The webcast will be made available for replay for 14 days
and can be accessed through the same link. About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
proprietary product candidates for the treatment of cancer and
infectious diseases. The Company seeks to improve the performance
and safety of existing treatments by addressing significant
problems such as drug metabolism, bioavailability, excessive
toxicity and treatment resistance. The Company's lead product
candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b clinical
trials for the treatment of metastatic colorectal cancer, as well
as in a Phase 2 clinical trial for the treatment of advanced breast
cancer. More information can be found on the Company's web site at
http://www.adventrx.com/. Forward Looking Statement ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors that, if they do not materialize or prove to be accurate,
could cause ADVENTRX's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties that could cause
actual results to differ materially include, but are not limited
to: uncertainties inherent in the drug development process; the
timing and success of clinical trials; the validity of research
results; the receipt of necessary approvals from the FDA and other
regulatory agencies; and other risks and uncertainties more fully
described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with
the Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Media, Amy Martini of WeissComm Partners, +1-212-301-7223,
for ADVENTRX Pharmaceuticals, Inc.; or Investors, Ioana C. Hone of
ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024